From: Terlipressin for septic shock patients: a meta-analysis of randomized controlled study
Groups | References | Patient number (TP/Ctrl) | Event (TP/Ctrl) | RR (95%CI) | I 2 | P | |
---|---|---|---|---|---|---|---|
Subgroup analyses | |||||||
Type of control | NE | [2, 8,9,10, 13, 21,22,23] | 425/413 | 200/202 | 0.95 (0.85,1.06) | 0% | 0.33 |
DA | [14, 20] | 46/44 | 27/28 | 0.92 (0.67,1.26) | 0% | 0.61 | |
Published year | After 2010 | [2, 5, 20,21,22,23] | 377/384 | 169/182 | 0.95 (0.84,1.07) | 8% | 0.40 |
Before 2010 | [9, 10, 13, 14] | 94/73 | 58/48 | 0.92 (0.74,1.16) | 0% | 0.49 | |
Study designed | Blinded | [8, 21] | 275/283 | 109/114 | 0.73 (0.31,1.72) | 79% | 0.48 |
Unblinded | [2, 9, 10, 13, 14, 20, 22, 23] | 196/174 | 118/116 | 0.93 (0.83,1.05) | 0% | 0.24 | |
TP dose | < 2 mg/d | [9, 10, 13, 22] | 95/71 | 47/36 | 0.92 (0.69,1.22) | 0% | 0.55 |
2–4 mg/d | [2, 8, 14, 20, 21] | 334/344 | 148/158 | 0.96 (0.82,1.12) | 0% | 0.61 | |
> 4 mg/d | [23] | 42/42 | 32/36 | 0.89 (0.72,1.10) | 0.27 | ||
Administration route | Bolus | [9, 13, 21] | 64/47 | 36/31 | 0.81 (0.46,1.40) | 51% | 0.44 |
Continuous infusion | [2, 8, 10, 14, 20, 22, 23] | 407/410 | 191/199 | 0.96 (0.86,1.07) | 0% | 0.42 | |
Sensitivity analyses | |||||||
28-day mortality | [2, 20, 22, 23] | 102/101 | 60/68 | 0.93 (0.81,1.07) | 0% | 0.34 | |
ICU mortality | [9, 10, 14] | 84/63 | 53/44 | 0.91 (0.72,1.14) | 0% | 0.41 | |
Hospital mortality | [13] | 10/10 | 5/4 | 1.25 (0.4,3.33) | 0.66 | ||
90-day mortality | [2] | 13/17 | 12/16 | 0.98 (0.81,1.19) | 0.85 | ||
More severe septic shock | [2, 9, 10, 13, 14] | 107/90 | 70/64 | 0.96 (0.82,1.11) | 0% | 0.55 | |
Less severe septic shock | [8, 20,21,22,23] | 364/367 | 157/166 | 0.72 (0.40,1.29) | 43% | 0.14 | |
Exclusion of the largest trial | [2, 9, 10, 13, 14, 20,21,22,23] | 211/191 | 123/129 | 0.91 (0.81,1.03) | 0% | 0.14 | |
Exclusion of pediatric patients | [2, 8,9,10, 13, 20,21,22,23] | 441/429 | 207/210 | 0.95 (0.85,1.05) | 0% | 0.31 |